Education
About Us
Working with TipRanks
Follow Us
Opyl Ltd. (AU:PKY)
ASX:PKY
PKY Stock Chart & Stats
AU$0.03
--
Market closed
AU$0.03
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.13M
Market Cap
AU$14.57M
Enterprise ValueAU$8.19M
Total Cash (Recent Filing)AU$580.84K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue PotentialOpyl’s stated go-to-market model emphasizes subscriptions, licensing and services, which are durable revenue streams if the company secures repeat customers. Over 2–6 months, converting customers to recurring contracts would improve predictability, enable operating leverage and support margin expansion as scale increases.
Alignment With Structural Industry TrendOpyl’s core focus on AI/ML for clinical trials targets a persistent industry need: more efficient patient identification and trial management. This secular trend supports long-term demand for analytics platforms and creates a sizable addressable market, improving the company's growth runway if it delivers validated outcomes.
Asset-light Technology Base And Small TeamA small, technology-focused team suggests an asset-light cost structure that can scale efficiently once product-market fit is achieved. Over several months this enables rapid iteration, lower fixed costs, and potential operating leverage as subscription revenue grows without large incremental headcount or capital investment.
Bears Say
Severe Revenue DeclineAn ~86% year‑over‑year revenue decline signals material loss of customer traction or project volume, undermining the business’s ability to scale recurring revenue. This structural top‑line deterioration raises the hurdle for achieving sustainable margins and limits near‑term prospects for self‑funding or profitable growth.
Persistent Negative Cash FlowConsistent negative operating and free cash flow, with a material YoY deterioration, indicates ongoing cash burn and an inability to generate internal funding. Over months this compels reliance on external financing, heightens dilution risk, and constrains investment in sales, product development, and customer scaling.
Balance Sheet FragilityNegative shareholders’ equity combined with rising debt reflects a fragile capital structure that reduces financial flexibility. If losses persist, the company faces solvency and counterparty risks, making long‑term contracts, partnerships or favorable financing terms harder to secure over a 2–6 month horizon.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$14.57M.
When is Opyl Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Opyl Ltd.’s earnings last quarter?
Currently, no data Available
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 607,077,760 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth AU$24.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.74%
12-Months-Change
Fundamentals
Return on Equity
-1268.85%
Trailing 12-Months
Asset Growth
129.09%
Trailing 12-Months
Company Description
Opyl Ltd.
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
Technical Analysis
Global Health Limited
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
InteliCare Holdings Limited
―